Abstract: A method for attaching lining elements to a structure exposed to wear using an interface engagement fastening arrangement is disclosed. The method involves the steps of attaching strips or sheets provided with a first part of the interface engagement fastening arrangement to a mounting surface of the structure; providing lining elements to the exposed first part of the interface engagement fastening arrangement so that these parts are inter-engaged. By this engagement of the first and second parts of the interface engagement fastening arrangement, the aimed-at lining element mounting is obtained.

Abstract: A lining element includes at least three layers and is configured to be mounted to a structure exposed to wear. The lining element has a wear-impeding polymer layer, an energy-absorbing polymer layer and a reinforcing polymer layer. The reinforcing layer is located adjacent the structure exposed to wear, whereas the energy-absorbing layer is located between the reinforcing layer and the wear-impeding layer. The wear-impeding layer is located on top of the energy-absorbing layer.

Abstract: A lining element includes at least three layers and is configured to be mounted to a structure exposed to wear. The lining element has a wear-impeding polymer layer, an energy-absorbing polymer layer and a reinforcing polymer layer. The reinforcing layer is located adjacent the structure exposed to wear, whereas the energy-absorbing layer is located between the reinforcing layer and the wear-impeding layer. The wear-impeding layer is located on top of the energy-absorbing layer.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.